| Abstrakt: |
In this special feature article, Steve Castellino and co‐authors highlight why matrix‐assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) technology is an important innovation, which can improve and enhance drug discovery and development. Currently, most IMS studies conducted in drug discovery and development focus on the quantitative distribution of drug candidates and their metabolites in animal model tissues. The need to understand the biodistribution of drugs in tissues is not a new concept, but historically, the analytical tools available to achieve this were limited. The introduction of IMS has addressed this gap by providing the ability to quantitatively characterize the distribution of drugs within tissues providing direct evidence of whether the drug is reaching the intended target. Thus, the aim of this special feature article is to share the authors collective experience in designing, conducting, and delivering impactful results using IMS in the preclinical space of pharmaceutical discovery and development. Dr. Stephen Castellino is currently Chief Analytics Officer at Glycopath (Charleston, South Carolina, USA). Dr Nichole M. Lareau is a Senior investigator and Dr Mark Reid Groseclose a Director in the Bioimaging group of GlaxoSmithKline (Collegeville, Pennsylvania, USA). [ABSTRACT FROM AUTHOR] |
